RT Journal Article
SR Electronic
T1 The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3592
VO 44
IS Suppl 58
A1 Petro Gerych
A1 Roman Yatsyshyn
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P3592.abstract
AB Background. We studed the effectiveness and safety of the roflumilast for patients with aggravated COPD, either uncomplicated or complicated by ischemic heart disease (IHD) manifested as stable exertional angina; the analysis is based on clinical symptomatology, the external respiratory function and cell-mediated immune parameters.Methods. The study involved 191 patients with a stage III COPD. 72 patients (23.03%) were diagnosed with comorbid IHD as stable angina (functional class III). The complex therapy includes roflumilast 500 mg during 6 monthes. Lymphocyte subpopulations were examined by indirect immunofluorescence method. The following monoclonal antibodies were used: CD3+, CD4+, CD8+, CD16+, CD22+.Result. The complex therapy resulted in an increase in the total number of T-lymphocytes as well as of separate populations. A rise in CD4+ lymphocytes to 1.22-2.54% led to the normalization of the immune-regulatory index. 76.0% of stage III COPD patients showed a tendency towards cell immunity improvement. The normalization of immunogram parameters manifested itself in a rise in the number of T-general lymphocytes as well as their separate subpopulations CD4+ and CD16+ lymphocytes (p<0.05 for both parameters).Conclusion. The use of roflumilast in complex treatment for both uncomplicated COPD and COPD complicated by IHD reduces clinical symptoms, improves cell-mediated immune parameters, stabilizes the external respiratory function, provides better treatment results.References:1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Last updated 2011.